Delving into the Latest Updates on Sichuan Zitonggong Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

5-HT1B receptor x 5-HT1D receptor	1

主要目的： 1、评价马甲子胶囊在晚期实体瘤患者中的安全性与耐受性； 2、确定最大耐受剂量（MTD）及II期临床试验推荐剂量（RP2D）次要目的： 1、研究马甲子胶囊在晚期实体瘤患者中单次给药与多次给药后的药代动力学（PK）特征； 2、确定剂量扩展研究的推荐剂量及瘤种； 3、评价马甲子胶囊在晚期实体瘤患者中的初步有效性

[Translation]

Main objectives: 1. To evaluate the safety and tolerability of Majiazi Capsules in patients with advanced solid tumors; 2. To determine the maximum tolerated dose (MTD) and the recommended dose (RP2D) for phase II clinical trials Secondary objectives: 1. To study the pharmacokinetic (PK) characteristics of Majiazi Capsules after single and multiple administrations in patients with advanced solid tumors; 2. To determine the recommended dose and tumor type for dose expansion studies; 3. To evaluate the preliminary effectiveness of Majiazi Capsules in patients with advanced solid tumors

Start Date20 Aug 2024

Sponsor / Collaborator

Sichuan Zitonggong Pharmaceutical Co., Ltd.

[+1]

CTR20221657 / CompletedNot Applicable

磷酸奥司他韦胶囊在健康受试者中单中心、开放、均衡、随机、单剂量、双周期、双交叉空腹状态下的生物等效性试验

[Translation] A single-center, open, balanced, randomized, single-dose, two-period, double-crossover bioequivalence study of oseltamivir phosphate capsules in healthy subjects under fasting conditions

主要目的：比较空腹给药条件下，四川梓橦宫药业股份有限公司生产的磷酸奥司他韦胶囊（75mg/粒）与Roche Pharma (Schweiz) AG持证的磷酸奥司他韦胶囊（75mg/粒，商品名：达菲®）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的：评价空腹给药条件下，四川梓橦宫药业股份有限公司生产的磷酸奥司他韦胶囊（75mg/粒）与参比制剂达菲®（75mg/粒）的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of oseltamivir phosphate capsules (75 mg/capsule) produced by Sichuan Ziligong Pharmaceutical Co., Ltd. and oseltamivir phosphate capsules (75 mg/capsule, trade name: Tamiflu®) certified by Roche Pharma (Schweiz) AG in healthy adults under fasting conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of oseltamivir phosphate capsules (75 mg/capsule) produced by Sichuan Ziligong Pharmaceutical Co., Ltd. and the reference preparation Tamiflu® (75 mg/capsule) under fasting conditions.

Start Date07 Jul 2022

Sponsor / Collaborator

Sichuan Zitonggong Pharmaceutical Co., Ltd.

CTR20213420 / CompletedNot Applicable

磷酸奥司他韦胶囊在健康受试者中单中心、开放、均衡、随机、单剂量、双周期、双交叉空腹及餐后状态下的生物等效性试验

[Translation] A single-center, open, balanced, randomized, single-dose, two-period, double-crossover bioequivalence study of oseltamivir phosphate capsules in healthy subjects under fasting and fed conditions

主要目的：比较空腹及餐后给药条件下，四川梓橦宫药业股份有限公司生产的磷酸奥司他韦胶囊（75mg/粒）与Roche Pharma (Schweiz) AG 持证的磷酸奥司他韦胶囊（75mg/粒，商品名：达菲®）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的：评价空腹及餐后给药条件下，四川梓橦宫药业股份有限公司生产的磷酸奥司他韦胶囊（75mg/粒）与参比制剂达菲®（75mg/粒）的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of oseltamivir phosphate capsules (75 mg/capsule) produced by Sichuan Ziligong Pharmaceutical Co., Ltd. and oseltamivir phosphate capsules (75 mg/capsule, trade name: Tamiflu®) certified by Roche Pharma (Schweiz) AG in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of oseltamivir phosphate capsules (75 mg/capsule) produced by Sichuan Ziligong Pharmaceutical Co., Ltd. and the reference preparation Tamiflu® (75 mg/capsule) under fasting and postprandial administration conditions.

Start Date16 Jan 2022

Sponsor / Collaborator

Sichuan Zitonggong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Sichuan Zitonggong Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sichuan Zitonggong Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Sichuan Zitonggong Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sichuan Zitonggong Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data